1-3 of 3
Samir Agrawal, PhD
Close
Sort by
Journal Articles

Reduced Dose PAD Combination Therapy (PS-341/Bortezomib, Adriamycin and Dexamethasone) for Previously Untreated Patients with Multiple Myeloma.

Rakesh Popat, MBBS, Heather E. Oakervee, MRCPath, Nicola Curry, MBBS, Nicola Foot, BSc, Curly Morris, FRCP, Mary Drake, MRCPath, Samir Agrawal, PhD, Patricia Smith, RGN, David Schenkein, MD, Dixie-Lee Esseltine, MD, Jamie D. Cavenagh, MD
Journal: Blood
Blood (2005) 106 (11): 2554.
https://doi.org/10.1182/blood.V106.11.2554.2554
Published: 2005
Journal Articles

A Phase I/II Study of Bortezomib and Low Dose Intravenous Melphalan (BM) for Relapsed Multiple Myeloma.

Rakesh Popat, DipRCPath, Heather E. Oakervee, MRCPath, Nicola Foot, BSc, Samir Agrawal, PhD, Patricia Smith, RGN, Charles Craddock, FRCPath, Catherine Williams, FRCPath, Supratik Basu, FRCPath, Jamie D. Cavenagh, MD
Journal: Blood
Blood (2005) 106 (11): 2555.
https://doi.org/10.1182/blood.V106.11.2555.2555
Published: 2005
Journal Articles

PAD Combination Therapy (PS-341/Bortezomib, Adriamycin and Dexamethasone) for Previously Untreated Patients with Multiple Myeloma.

James D. Cavenagh, MD, Rakesh Popat, MB BS, Nikki Curry, MB BS, Jim Stec, PhD, Treen C. Morris, FRCP, Mary Drake, MRCPath, Samir Agrawal, PhD, Patricia Smith, RGN, David P. Schenkein, MD, Dixie-Lee Esseltine, MD, Heather Oakervee, MRCP
Journal: Blood
Blood (2004) 104 (11): 1478.
https://doi.org/10.1182/blood.V104.11.1478.1478
Published: 2004